Ultragenyx Pharmaceutical Inc. Stock
There is no change in the price for Ultragenyx Pharmaceutical Inc. today.
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
Based on the current price of 30.8 € the target price of 78 € shows a potential of 153.25% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Ultragenyx Pharmaceutical Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 0.000% | -7.784% | 9.220% | -29.032% | -25.604% | -28.037% | -75.556% |
| Ironwood Pharmaceuticals | -1.960% | 2.740% | 10.294% | -9.091% | -28.571% | -73.554% | -70.000% |
| Novocure Ltd | -2.160% | 6.509% | 13.422% | -65.322% | -62.071% | -84.260% | -91.438% |
| Iovance Biotherapeutics Inc. | -2.550% | -7.402% | -14.239% | -75.429% | -73.443% | -71.732% | -95.333% |
Comments
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at TD Cowen from $86.00 to $75.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Truist Financial Corporation from $100.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx (RARE) Q2 Revenue Up 13%
Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street
